<?xml version="1.0" encoding="UTF-8"?>
<p id="Par2">Late-onset sporadic forms of neurodegenerative diseases are devastating conditions imposing an increasing burden on healthcare systems worldwide. Currently, 2–3% of the population over 65 years of age are living with Parkinson’s disease (PD), making this disorder the most prevalent late-onset neurodegenerative disorder worldwide after Alzheimer’s disease.
 <sup>
  <xref ref-type="bibr" rid="CR1">1</xref>
 </sup> This progressive condition is characterised by the loss of dopaminergic neurons in the substantia nigra pars compacta manifesting clinically as a tremor at rest, muscle rigidity and bradykinesia.
 <sup>
  <xref ref-type="bibr" rid="CR1">1</xref>,
  <xref ref-type="bibr" rid="CR2">2</xref>
 </sup> Existing symptomatic treatments do not alter the course of the disease and their effectiveness declines with time, which makes the identification of potential therapeutic targets of key importance.
</p>
